Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

Blood (2013) 122 (21): 524.

https://doi.org/10.1182/blood.V122.21.524.524

Published: 2013

Journal Articles

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

Hatice Duzkale, Carmen D. Schweighofer, Kevin R. Coombes, Lynn L. Barron, Alessandra Ferrajoli, Susan O'Brien, William G. Wierda, John Pfeifer, Tadeusz Majewski, Bogdan A. Czerniak, Jeffrey L. Jorgensen, L. Jeffrey Medeiros, Emil J Freireich, Michael J. Keating, Lynne V. Abruzzo

Blood (2011) 117 (15): 4076–4084.

https://doi.org/10.1182/blood-2010-09-304881

Published: 2011

Includes: Supplemental data

Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Blood (2009) 114 (16): 3382–3391.

https://doi.org/10.1182/blood-2009-02-206185

Published: 2009

Includes: Supplemental data

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group

Blood (2008) 112 (11): 330.

https://doi.org/10.1182/blood.V112.11.330.330

Published: 2008

Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 2053.

https://doi.org/10.1182/blood.V110.11.2053.2053

Published: 2007

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 3106.

https://doi.org/10.1182/blood.V110.11.3106.3106

Published: 2007

Journal Articles

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Martina Stauch, MD, Manuela Bergmann, MD, Matthias Ritgen, MD, Nicole Kranzhöfer, MD, Carmen D. Schweighofer, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Paula Cramer, Valentin Goede, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 629.

https://doi.org/10.1182/blood.V110.11.629.629

Published: 2007

NARROW

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only